摘要
目的 :观察腺苷蛋氨酸 (SAMe)治疗慢性肝炎及肝炎肝硬化合并黄疸患者的疗效 ,重点观察退黄效果。方法 :慢性肝炎、肝炎肝硬化病人共 146例 ,血清总胆红素均 >85 ︼mol/ L。其中慢性肝炎治疗组 40例 ,对照组 38例 ;肝炎肝硬化治疗组 36例 ,对照组 32例。治疗组用 SAMe 5 0 0 m g,iv gtt,bid,疗程 6 wk。对照组用天冬氨酸钾镁 (PMA ) 2 0 ml,iv gtt,qd;疗程 6wk。结果 :SAMe治疗慢性肝炎与对照组比较血清总胆红素 (TB)、谷丙转氨酶 (AL T)、γ谷氨酰转移酶 (γ- GT)、碱性磷酸酶(AL P)、白蛋白 (AL B)分别 P<0 .0 1、P<0 .0 5、P>0 .0 5、P<0 .0 5、P>0 .0 5。肝硬化 2组比较分别 P<0 .0 5、P>0 .0 5、P>0 .0 5、P>0 .0 5、P>0 .0 5。结论 :SAMe治疗慢性肝炎、肝硬化安全有效 ,对慢性肝炎疗效优于肝硬化 ,尤以退黄效果为佳。
AIM: To observe the therapeutic efficacy of S adenosyl L methionine (SAMe) in chronic hepatitis (CH) and liver cirrhosis (LC) with jaundice, especially its efficacy in reducing serum total bilirubin (TB). METHODS: One hundred and forty six patients with CH and LC entered the trial, whose TB were all higher than 85 μmol/L. Forty cases in CH and 36 cases in LC were treated with intravenous SAMe 500 mg, bid for 6 wk, while 38 cases in CH and 32 cases in LC were given intravenous potassium magnesium asparate (PMA) 20 ml/d for 6 wk. RESULTS: The serum levels of TB, ALT, ALP of SAMe group with CH were all improved comparing with PMA group, respectively ( P <0 01, P <0 05, P <0 05). As for patients with LC, the TB were lower in SAMe group ( P <0 05), while the serum level of ALT, γ GT, ALP, ALB was not different. CONCLUSION: SAMe is safe and effective in treatment of both CH and LC, the therapeutic efficacy was better in CH, especially in reducing TB.
出处
《中国临床药学杂志》
CAS
2000年第6期335-338,共4页
Chinese Journal of Clinical Pharmacy
关键词
腺苷蛋氨酸
慢性肝炎
肝硬化
胆红素
治疗
S adenosyl L methionine
chronic hepatitis
liver cirrhosis
billirubin
